StemCell Therapy

H

ello, everyone, and how are you today? We are doing just fine, thank you, especially now that the Pharmalot campus has quieted down. Both Mrs. Pharmalot and the shortest person have left for their respective destinations, and the official mascots are snoozing contentedly in their usual spots. This leaves us to forage for interesting items for you. On that note, here are some tidbits. Have a wonderful day and do let us know about juicy developments

An experimental rheumatoid arthritis drug from Johnson & Johnson was linked to more deaths than a placebo, Food and Drug Administration staff reviewers wrote in an advance of a Wednesday expert panel meeting, Reuters writes. Other possiblesafety issues were similar to other drugs in the class, but the trend of increased overall mortality seems unique for this medicine, they wrote.The most common causes of death were major heart problems, infection, and malignancies.

This is a STAT Plus article and is only available to STAT Plus subscribers.To read the full story, subscribe to STAT Plus or log in to your account.Good news: your first 30 days are on us.

Pharmalot Columnist, Senior Writer

Ed covers the pharmaceutical industry.

Read more here:
Pharmalittle: FDA staff cautious on J&J arthritis drug; Kite seeks EU nod for CAR-T drug - STAT

This entry was posted on August 1, 2017 at 7:49 pm and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |